Adaptimmune Therapeutics PLC — Director's Dealing 2023

Jan 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2023-01-17

Reporting Person: Brewer Joanna Elizabeth (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-17	Option to purchase Ordinary Shares	$0.31	A	1407072	Acquired	2033-01-17	Ordinary Shares (1407072)	Direct
2023-01-17	Option to purchase Ordinary Shares	$0.0012	A	314256	Acquired	2033-01-17	Ordinary Shares (314256)	Direct
2023-01-17	Option to purchase Ordinary Shares	$0.0012	A	135480	Acquired	2033-01-17	Ordinary Shares (135480)	Direct

Footnotes

F1: The exercise price was converted from GBP0.26 based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 351,768 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in monthly installments of 29,310 Ordinary Shares on the seventeenth of each month from February 17, 2024 through December 17, 2026 and 29,454 Ordinary Shares on January 17, 2027.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 78,564 Ordinary Shares on January 17, 2024 and will be exercisable as to the remainder in annual installments of 78,564 Ordinary Shares on the seventeenth of each January from January 17, 2025 through January 17, 2027.

F5: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.219333 to GBP1.00. The actual exercise price will be the pounds sterling amount.